Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metreleptin - Novelion Therapeutics

Drug Profile

Metreleptin - Novelion Therapeutics

Alternative Names: Human recombinant methionyl leptin; Methionyl human leptin; Myalept; MYALEPTA; r-metHuLeptin; Recombinant methionyl human leptin

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Beth Israel Deaconess Medical Center; Novelion Therapeutics; Shionogi; University of Texas Southwestern Medical Center
  • Class Adipokines; Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies; Recombinant proteins
  • Mechanism of Action Glucose modulators; Hormone modulators; Leptin receptor agonists; Leptin replacements; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lipodystrophy
  • Phase II Amenorrhoea
  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 31 Jul 2018 Registered for Lipodystrophy in European Union, Norway, Iceland, Liechtenstein (SC)
  • 26 Jun 2018 Efficacy and adverse events data from a clinical trial in Lipodystrophy released by Novelion Therapeutics
  • 26 Jun 2018 Novelion Therapeutics initiates enrolment in a clinical trial for Lipodystrophy (Before June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top